Dados B3 › BIOM3 × HYPE3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | BIOM3 | HYPE3 | year |
|---|---|---|---|
| ROE | -2.3% | 9.7% | 2025 |
| ROIC | -1.1%! | 8.8%! | 2025 |
| ROA | -1.4% | 4.8% | 2025 |
| Gross margin | 31.6% | 59.0% | 2025 |
| EBIT margin | -1.9% | 22.9% | 2025 |
| Net margin | -2.5% | 15.5% | 2025 |
| Net debt/EBITDA | 16.05x | 3.68x | 2025 |
| Current ratio | 2.23x | 1.47x | 2025 |
| Revenue growth (1y) | 88.4% | 3.4% | 2025 |
| Revenue growth (5y CAGR) | 35.6% | 13.5% | 2025 |
| Piotroski F-Score | 4/9 | 7/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | BIOM3 | HYPE3 | year |
|---|---|---|---|
| P/E | -146.52x | 11.30x | 2025 |
| P/B | 3.13x | 1.08x | 2025 |
| EV/EBITDA | 310.46x | 10.17x | 2025 |
| FCF yield | -14.1% | 13.1% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:49 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it